Emeline Tabouret

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2026

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Journal: Discover oncology

Published: November 24, 2025

Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Journal: Bulletin du cancer

Published: October 07, 2025

Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.

Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 07, 2025

Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935.

Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935.

Journal: Cancers

Published: September 15, 2025

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Journal: Journal of neuro-oncology

Published: August 26, 2025

Movement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review.

Movement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review.

Journal: Revue neurologique

Published: July 29, 2025

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.

Journal: Neuro-oncology

Published: July 22, 2025

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 13, 2025

From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.

From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 11, 2025

3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.

3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.

Journal: The Journal of clinical endocrinology and metabolism

Published: July 02, 2025

Partial or full preservation of the pituitary stalk in craniopharyngioma surgery: improving endocrinological outcomes without an increased risk of recurrence.

Partial or full preservation of the pituitary stalk in craniopharyngioma surgery: improving endocrinological outcomes without an increased risk of recurrence.

Journal: Journal of neurosurgery

Published: June 11, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026